Studies have demonstrated that serum cystatin C is a sensitive biomarker for detecting changes in GFR and identifying preclinical renal disease, particularly in diabetic patients with a normal serum creatinine concentration [9]. This evidence concerns the gene CST3 and kidney disorder.